Floatz logo

PRILOCAINE

Drug Use

Francesco BonoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Drug Use cohort.

Asset / SponsorPhaseRating
Eloxatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Bont-A
Francesco Bono
Phase 2CCC
Irinotecan
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC

Same molecule, other indications

PRILOCAINE is also rated in:

Leukemia-LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Migraine DisordersDormant
BB
Indicative ·
64 / 100
View asset →
Non Hodgkin LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →